Skip to main content

Health Catalyst, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

HCAT$1.51+3.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 5. Other Information

(a) None.

(b) None.

(c) During the three months ended September 30, 2026, the following directors or officers of the Company adopted a “Rule 10b5-1 trading arrangement”, as defined in Item 408(a) of Regulation S-K:

Name and TitleType of Trading ArrangementDate AdoptedExpiration DateDuration(1)Total Shares to be Sold
Benjamin Landry, General CounselRule 10b5-1 Trading Arrangement8/12/20269/15/2027399 daysUp to 283,729(2)

(1)The Rule 10b5-1 trading arrangement permits transactions through and including the earlier to occur of (a) completion of all sales or (b) the expiration date listed in the table.

(2)The 10b5-1 trading arrangement provides for the sale of 71,687 shares of common stock, and net vested shares from certain performance-based restricted stock units (PRSU) awards and certain restricted stock unit (RSU) awards as well as the net number of shares resulting from purchases under the Company’s Employee Stock Purchase Plan (ESPP). With respect to the PRSU awards, total shares to be sold reflects a maximum amount that could potentially vest without taking into account that such number is subject to the level of achievement of each performance goal contained within such PRSU awards as well as the number of shares that will be surrendered to the Company or automatically sold to satisfy applicable tax withholding obligations upon vesting of the PRSU awards, which will vary based on the market price of the Company’s common stock at the time of vesting. With respect to the RSU awards, total shares to be sold reflects a maximum amount that includes shares that will be surrendered to the Company or automatically sold to satisfy applicable tax withholding obligations upon vesting of the RSU awards, which will vary based on the market price of the Company’s common stock at the time of vesting. With respect to the ESPP, the total shares to be sold is up to 5,000 shares (i.e., the maximum number of shares that could be acquired under the ESPP for the period ending on the expiration date of the Rule 10b5-1 trading arrangement), and such number will vary based on the market price of the Company’s common stock at the time of the acquisition of shares under the ESPP.

There were no “non-Rule 10b5-1 trading arrangements,” as defined in Item 408(c) of Regulation S-K, adopted, terminated, or modified by our directors or officers during the three months ended September 30, 2026.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.